학술논문
Tinzaparin in cancer associated thrombosis beyond 6 months: TiCAT study.
Document Type
Article
Author
Jara-Palomares, Luis; Solier-Lopez, Aurora; Elias-Hernandez, Teresa; Asensio-Cruz, Maribel; Blasco-Esquivias, Isabel; Marin-Barrera, Lucia; de la Borbolla-Artacho, Maria Rodriguez; Praena-Fernandez, Juan Manuel; Montero-Romero, Emilio; Navarro-Herrero, Silvia; Serrano-Gotarredona, Maria Pilar; Sánchez-Díaz, José María; Palacios, Carlos; Otero, Remedios
Source
Subject
*CARDIOVASCULAR disease treatment
*THROMBOSIS
*HEPARIN
*DRUG efficacy
*DISEASE relapse
*DISEASE incidence
*
*
*
*
*
Language
ISSN
0049-3848
Abstract
Introduction The safety and efficacy of low-molecular-weight heparin (LMWH) treatment in patients with cancer-associated thrombosis (CAT) beyond 6 months are unknown. Our aim was to determine the safety of long-term tinzaparin use in patients with CAT. Methods We performed a prospective, open, single arm, multicentre study in patients with CAT receiving treatment with tinzaparin. We evaluated the rate of clinically relevant bleeding events (major and non-major clinically relevant bleeding) and venous thromboembolism (VTE) recurrence. Results A total of 247 patients were recruited, with a crude incidence of major bleeding of 4.9% (12/247). The rate of clinically relevant bleeding during months 1–6 and 7–12, was 0.9% [95% confidence interval (95% CI) 0.5 to 1.6%] and 0.6% (95% CI 0.2 to 1.4%) ( p = 0.5) per patient and month, respectively. Male gender showed greater risk for clinically relevant bleeding with a hazard ratio (HR) of 2.97 (95% CI 1.01 to 8.1; p = 0.02). The incidence of VTE recurrence at months 1–6 and 7–12 was 4.5% (95% CI 2.2 to 7.8%) and 1.1% (95% CI 0.1 to 3.9%), respectively. One patient died due to VTE recurrence and two because of severe bleeding. Conclusions Treatment with tinzaparin beyond 6 months is safe in patients with CAT. [ABSTRACT FROM AUTHOR]